invoX CEO Ben Toogood (L) and F-star CEO Eliot Forster
July 8, 2022 09:17 AM EDTUpdated 03:02 PM
Deals
Bioregnum

A por­trait of a biotech buy­out deal in sav­age times: turn­ing a $15.50 of­fer in­to a $7.12 deal

Back last No­vem­ber, the once high-fly­ing F-star was hurt­ing, bad. Its share price had been crushed and the CEO, Eliot Forster of Im­muno­core fame, had …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times